Clinical trials: HFpEF - Heart Failure with Preserved Ejection Fraction
Heart Failure With Preserved Ejection Fraction
Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction
The purpose of this study was to evaluate the effect of LCZ696 compared to valsartan in the reduction of cardiovascular death and heart failure(HF) hospitalizations in patients with HF with preserved ejection fraction.
- Trial name
- PARAGON-HF (NCT01920711)
- Testing
- LCZ696, Valsartan
- Where
- 715 sites in United States, Argentina and 41 more
- Volunteers
- 4,822 people
- Sponsor
- Novartis Pharmaceuticals
Heart Failure, Heart Failure With Preserved Ejection Fraction
EMPAGUM: Effects of Empagliflozin on Gut Microbiota in Heart Failure With a Preserved Ejection Fraction
Empagliflozin was recommended for patients with heart failure with reduced ejection fraction (HFrEF) in 2021 European Society of Cardiology (ESC) guidelines (Class of Recommendation Ia) and patients with heart failure with…
- Trial name
- NCT05584319
- Testing
- Empagliflozin 10 Mg
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Zhijun Sun
Heart Failure (HF)
A Trial to Study BAY1753011 in Patients With Congestive Heart Failure
To assess the efficacy of 30 mg of BAY1753011, with or without furosemide, versus furosemide alone in patients with heart failure and objective evidence of congestion.
- Trial name
- AVANTI (NCT03901729)
- Testing
- BAY 1753011, Furosemide
- Where
- 66 sites in Austria, Bulgaria and 7 more
- Volunteers
- 482 people
- Sponsor
- Bayer
Heart Failure With Normal Ejection Fraction, Obesity
Unsaturated Fatty Acids Enriched-diet to Improve Cardiorespiratory Fitness, Metabolic Flexibility and Glucose Tolerance in Obese Patients
The investigators hypothesize that a dietary intervention aimed at increasing unsaturated fatty acids (UFA) consumption is feasible and has the potential to improve cardiorespiratory fitness, metabolic flexibility and glucose…
- Trial name
- NCT03310099
- Testing
- Increasing daily unsaturated fatty acid consumption
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Virginia Commonwealth University
Heart Failure, Heart Failure With Preserved Ejection Fraction
Assessment of CCM in HF With Higher Ejection Fraction
The AIM HIGHer Clinical Trial will evaluate the safety and efficacy of Cardiac Contractility Modulation (CCM) therapy in patients with heart failure with LVEF ≥40% and ≤70%.
- Conditions
- Heart Failure, Heart Failure With Preserved Ejection Fraction, Heart Failure With Mid Range Ejection Fraction, Heart Failure With Moderately Reduced Ejection Fraction
- Trial name
- AIM HIGHer (NCT05064709)
- Testing
- Cardiac Contractility Modulation Therapy via OPTIMIZER™ Smart Mini System, OPTIMIZER™ Smart Mini System
- Where
- 67 sites in United States
- Volunteers
- 1,500 people
- Sponsor
- Impulse Dynamics
Transthyretin Amyloidosis, Heart Failure
Prevalence and Prediction of ATTR in Ambulatory Patients With HFpEF
Recent studies have shown that transthyretin amyloidosis (ATTR) can sometimes cause a type of heart failure where the pumping function of the heart is normal, also known as Heart Failure with Preserved Ejection Fraction (HFpEF)…
- Conditions
- Transthyretin Amyloidosis, Heart Failure, Heart Failure, Diastolic, Amyloidosis
- Trial name
- TTRinHFpEF (NCT05577819)
- Testing
- 99mTc-pyrophosphate Scintigraphy
- Where
- United States
- Volunteers
- 515 people
- Sponsor
- Massachusetts General Hospital
Heart Failure, Heart Failure With Preserved Ejection Fraction
Randomized Controlled Pilot Trial of DASH Feeding in Older Low Socioeconomic Adults Without Heart Failure
This is a study of the DASH diet (Dietary Approaches to Stop Hypertension) in the exploration of effective strategies for Heart failure (HF) with preserved ejection fraction (HFPEF) prevention.
- Trial name
- DASHF (NCT04113291)
- Testing
- DASH Diet, Usual diet
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Wake Forest University Health Sciences
Cardiovascular Disease
A Study to Assess the Mass Balance Recovery, Pharmacokinetics, Metabolite Profile and Metabolite Identification of [14C]AZD4831
The Sponsor is developing the test medicine, AZD4831, for the potential treatment of cardiovascular disease (CVD). CVD is a general term to describe a range of conditions that affect the heart and blood vessels, examples of CVD…
- Trial name
- NCT04407091
- Testing
- 14C]AZD4831 Oral Solution
- Where
- United Kingdom
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Hypertension Pulmonary Secondary, Heart Failure, Right Sided
Hemodynamic Evaluation of Levosimendan in Patients With PH-HFpEF
Phase 2 study to evaluate the efficacy and safety of intermittent levosimendan compared with placebo in hemodynamic improvement with exercise in PH-HFpEF subjects
- Conditions
- Hypertension Pulmonary Secondary, Heart Failure, Right Sided, Heart Failure With Normal Ejection Fraction
- Trial name
- HELP (NCT03541603)
- Testing
- Levosimendan
- Where
- 16 sites in United States
- Volunteers
- 44 people
- Sponsor
- Tenax Therapeutics, Inc.
Heart Failure
BAROSTIM THERAPY™ In Heart Failure With Preserved Ejection Fraction
The purpose of this registry (NCT02876042) is to evaluate the effect of BAROSTIM THERAPY with the BAROSTIM NEO system in the commercial setting in subjects recently implanted under the CE-Marked indication for resistant…
- Trial name
- HFpEF (NCT02876042)
- Testing
- BAROSTIM NEO™ System
- Where
- 13 sites in Germany
- Volunteers
- 11 people
- Sponsor
- CVRx, Inc.
Heart Failure With Preserved Ejection Fraction, Concentric Hypertrophy
Fast Induced Remodeling in Heart Failure With Preserved Ejection Fraction
FIRE-HFpEF is a multi-center, prospective, randomized, single-blinded, clinical feasibility study. This study will enroll up to 105 subjects with heart failure with preserved ejection fraction in the United States.
- Trial name
- FIRE-HFpEF (NCT05839730)
- Testing
- Pacemaker PLR + TRT ON, Pacemaker non-pacing mode or an exertional rate-adaptive pacing mode with no planned pacing at rest.
- Where
- 8 sites in United States
- Volunteers
- 105 people
- Sponsor
- Medtronic Cardiac Rhythm and Heart Failure
Heart Failure With Reduced Ejection Fraction, Heart Failure With Preserved Ejection Fraction
Exercise Capacity Improvement by Conduction System Pacing in heArt Failure patieNts Without Compelling CRT inDication
This randomized controlled trial aims to investigate the impact of conduction system pacing in comparison to right ventricular apical pacing on exercise capacity, as measured by peak oxygen uptake (VO2peak), in heart failure…
- Conditions
- Heart Failure With Reduced Ejection Fraction, Heart Failure With Preserved Ejection Fraction, Heart Conduction Disorder
- Trial name
- ESCPAND (NCT06278844)
- Testing
- Conduction system pacing, Right ventricular apical pacing
- Where
- Belgium
- Volunteers
- 75 people
- Sponsor
- University Hospital, Antwerp
Heart Failure With Preserved Ejection Fraction
Single-Ascending Dose Study of JK07 in Subjects With HFpEF
A phase 1, randomized, double-blind, placebo-controlled single-ascending dose study to assess JK07 in adult subjects with heart failure with preserved ejection fraction.
- Trial name
- NCT05322616
- Testing
- JK07
- Where
- 7 sites in United States
- Sponsor
- Salubris Biotherapeutics Inc
Pulmonary Hypertension
LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF
This study will evaluate the efficacy of TNX-103 (oral levosimendan) compared with placebo in subjects with PH-HFpEF as measured by the change in 6-Minute Walk Distance (6 MWD; Day 1 to Week 12).
- Trial name
- LEVEL (NCT05983250)
- Testing
- TNX-103
- Where
- 42 sites in United States, Canada
- Volunteers
- 230 people
- Sponsor
- Tenax Therapeutics, Inc.
Heart Failure With Preserved Ejection Fraction, Heart Failure, Congestive
Evaluation of Enalapril Versus Placebo in Patients With Diastolic Heart Failure
BACKGROUND: Exercise intolerance is the primary symptom in older patients with heart failure and preserved ejection fraction (HFPEF), however little is known regarding its mechanisms and therapy.
- Trial name
- PIE-I (NCT01411735)
- Testing
- Enalapril
- Volunteers
- 71 people
- Sponsor
- Wake Forest University
Heart Failure With Normal Ejection Fraction
Inhaled Iloprost and Exercise Hemodynamics and Ventricular Performance in Heart Failure With Preserved Ejection Fraction
BACKGROUND There is no effective medical treatment for heart failure with preserved ejection fraction (HFpEF). Increases in pulmonary capillary wedge pressure (PCWP) develop in patients with HFpEF.
- Trial name
- ILO-HOPE (NCT03620526)
- Testing
- Iloprost
- Where
- Taiwan
- Volunteers
- 34 people
- Sponsor
- National Taiwan University Hospital
Heart Failure, Diastolic, Diabetes Mellitus, Type 2
Effects of Empagliflozin on Exercise Capacity and Left Ventricular Diastolic Function in Patients With Heart Failure With Preserved Ejection Fraction and Type-2 Diabetes Mellitus
Patients enrolled into the study will be randomly allocated either to Empagliflozin group or control group. In the Empagliflozin group patients will be receiving standard care + Empagliflozin 10 mg o.d., in the control group…
- Trial name
- NCT03753087
- Testing
- Empagliflozin, Standard care
- Where
- Russia
- Volunteers
- 70 people
- Sponsor
- National Medical Research Center for Cardiology, Ministry of Health of Russian Federation
Transthyretin Amyloid Cardiomyopathy, Heart Failure With Preserved Ejection Fraction
Global Prevalence of ATTR-CM in Participants With HFpEF
This study is a global, multi-center study designed to estimate the global prevalence of transthyretin amyloid cardiomyopathy (ATTR-CM) within a clinically at risk population [participants with heart failure with preserved…
- Trial name
- NCT04424914
- Testing
- Scintigraphy
- Where
- 51 sites in United States, Canada and 6 more
- Volunteers
- 347 people
- Sponsor
- Pfizer
Heart Failure, Diastolic, Pulmonary Hypertension
Sildenafil in HFpEF (Heart Failure With Preserved Ejection Fraction) and PH
Aim of the study is to investigate whether Sildenafil treatment results in a reduction of pulmonary artery pressure without decrease of cardiac output (CO) and in improvement of exercise capacity in patients with heart failure…
- Trial name
- NCT01726049
- Testing
- Sildenafil
- Where
- Netherlands
- Volunteers
- 52 people
- Sponsor
- University Medical Center Groningen
Heart Failure With Preserved Ejection Fraction
Study of Sacubitril/ValsarTan on MyocardIal OxygenatioN and Fibrosis in Heart Failure With Preserved Ejection Fraction
To assess the effect of ARNI on myocardial deoxygenation at stress and myocardial fibrosis, and correlate this to changes in myocardial systolic and diastolic function in HFpEF patients.
- Trial name
- PRISTINE-HF (NCT04128891)
- Testing
- Sacubitril-Valsartan
- Sponsor
- Flinders University